InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Xilio Therapeutics, Inc.

XLO Clue Score45
United States Fiscal year ends December CIK 0001840233
$9.05 +0.44% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $9.05 −43.44% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 22 Oct 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2020Operating income−54.6Net income−55.2EPS, diluted−105.42Fiscal year 2021Operating income−75.0Net income−75.8EPS, diluted−13.52Fiscal year 2022Operating income−89.1Net income−88.2EPS, diluted−3.22Fiscal year 2023Operating income−79.1Net income−76.4EPS, diluted−2.78Fiscal year 2024Revenue6.3Operating income−60.6Net income−58.2EPS, diluted−15.24Fiscal year 2025Revenue43.8 +589.9%Operating income−42.0Net income−35.0EPS, diluted−4.19
FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a n/a n/a 6.3 43.8
Growth +589.9%
Operating income −54.6 −75.0 −89.1 −79.1 −60.6 −42.0
Net income −55.2 −75.8 −88.2 −76.4 −58.2 −35.0
Growth
EPS, diluted −105.42 −13.52 −3.22 −2.78 −15.24 −4.19
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2020Fiscal year 2021Fiscal year 2022Fiscal year 2023Fiscal year 2024Operating margin−954.9%Net margin−918.0%Free cash flow margin−290.3%Fiscal year 2025Operating margin−95.9%Net margin−80.1%Free cash flow margin−12.6%
FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a n/a −954.9% −95.9%
Net margin n/a n/a n/a n/a −918.0% −80.1%
Free cash flow margin n/a n/a n/a n/a −290.3% −12.6%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow−36.1Capital expenditure−2.2Free cash flow−38.3Fiscal year 2021Operating cash flow−80.8Capital expenditure−1.1Free cash flow−81.9Fiscal year 2022Operating cash flow−75.7Capital expenditure−1.9Free cash flow−77.6Fiscal year 2023Operating cash flow−68.6Capital expenditure−0.5Free cash flow−69.1Fiscal year 2024Operating cash flow−18.4Capital expenditure−0.0Free cash flow−18.4Fiscal year 2025Operating cash flow−5.0Capital expenditure−0.5Free cash flow−5.5
FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −36.1 −80.8 −75.7 −68.6 −18.4 −5.0
Capital expenditure −2.2 −1.1 −1.9 −0.5 −0.0 −0.5
Free cash flow −38.3 −81.9 −77.6 −69.1 −18.4 −5.5
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2020Cash19.2Shareholders’ equity−83.3Fiscal year 2021Cash198.1Shareholders’ equity185.4Fiscal year 2022Cash120.4Shareholders’ equity105.6Fiscal year 2023Cash44.7Shareholders’ equity36.8Fiscal year 2024Cash55.3Shareholders’ equity17.6Fiscal year 2025Cash137.5Shareholders’ equity35.3
FY2020FY2021FY2022FY2023FY2024FY2025
Cash 19.2 198.1 120.4 44.7 55.3 137.5
Shareholders’ equity −83.3 185.4 105.6 36.8 17.6 35.3

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Balance sheet

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Assets
19.2 198.1 120.4 44.7 55.3 137.5
7.4 7.6 7.3 5.9 4.5 3.9
36.3 218.1 139.2 60.9 71.1 154.7
Growth +500.4% −36.2% −56.2% +16.7% +117.6%
Liabilities
41.6 32.6 33.5 24.1 53.5 119.4
Equity
−85.1 −160.9 −249.1 −325.5 −383.8 −418.8
−83.3 185.4 105.6 36.8 17.6 35.3
Growth −43.0% −65.1% −52.2% +100.4%
Per share and net cash
0.7 27.4 27.4 27.6 3.3 4.5
calc −120.72 6.78 3.85 1.33 5.38 7.79

Lines marked calc are worked out here from filed figures; point at one for how.